To evaluate the hormone profile of young men with the chief complaint of erectile dysfunction (ED) and determine the comorbidities in this population.
A retrospective chart review of men aged 18-40 years who presented with ED and had a hormone evaluation but without prior medication for hormone manipulation from 2002-2016 at a tertiary care institution. Data was obtained on demographics, co-morbidities, medications, and hormonal evaluations.
A total of 2,292 ED men were identified and 2130 of them received testosterone level evaluation. The most common comorbidities that men were actively being treated for were depression (22.3%), anxiety (16.1%), hypertension (15.6%), diabetes (7.2%), cancer (6.2%), and cardiovascular disease (3.3%). The average total testosterone level was 368 ± 160 ng/dL. 10.7% of men had hypogonadism. Multivariate analysis demonstrated age, body mass index (BMI), depression and cancer predicted a hypogonadal status. Patients with BMI > 28.2 kg/m, age > 34 years, cancer diagnosis or depression were 3.350-fold, 1.447-fold, 2.317-fold or 1.420-fold more likely to be diagnosed hypogonadal than non-overweight, age <=34 years, non-cancer or non-depressive patients.
The majority of men under age 40 with ED exhibit a normal hormonal milieu. Young ED men with BMI > 28.2 kg/m, age >34 years, cancer diagnosis or depression are at risk for hypogonadism.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Journal of the Chinese Medical Association : JCMA. 2019 Mar 28 [Epub ahead of print]
I-Shen Huang, Daniel J Mazur, Barbara E Kahn, Mary Kate Keeter, Anuj S Desai, Kevin Lewis, Alexander J Tatem, Marah C Hehemann, Robert E Brannigan, Nelson E Bennett
Departments of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA., Loyola Medicine Chicago Stritch School of Medicine, Chicago, IL, USA.